期刊
LUNG CANCER
卷 86, 期 1, 页码 113-114出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2014.07.021
关键词
Erlotinib; Interstitial lung disease; Pharmacokinetics; High exposure; ABCG2; Polymorphism
分享论文
